Applied Genetic Technologies Corporation (AGTC) financial statements (2020 and earlier)
Company profile
| Business Address |
14193 NW 119TH TERRACE ALACHUA, FL 32615 |
| State of Incorp. | DE |
| Fiscal Year End | June 30 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2019 TTM | 6/30/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments, including: | 71 | 82 | 105 | 127 | 99 | 62 | ||
| Cash and cash equivalents | 16 | 27 | 31 | 31 | 29 | 39 | ||
| Short-term investments | 55 | 55 | 74 | 96 | 70 | 22 | ||
| Other undisclosed cash, cash equivalents, and short-term investments | (0) | 0 | ||||||
| Receivables | 0 | 0 | 0 | 0 | 1 | 1 | ||
| Other undisclosed current assets | 2 | 2 | 4 | 3 | 3 | 2 | ||
| Total current assets: | 73 | 84 | 109 | 130 | 103 | 64 | ||
| Noncurrent Assets | ||||||||
| Finance lease, right-of-use asset | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Operating lease, right-of-use asset | 4 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Nontrade receivables | 0 | |||||||
| Property, plant and equipment | 4 | 4 | 5 | 3 | 3 | 0 | ||
| Long-term investments and receivables | 2 | 12 | 74 | 24 | ||||
| Long-term investments | 2 | 12 | 74 | 24 | ||||
| Intangible assets, net (including goodwill) | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Intangible assets, net (excluding goodwill) | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Other noncurrent assets | 1 | 1 | 1 | 0 | 0 | 0 | ||
| Other undisclosed noncurrent assets | 2 | 2 | 2 | |||||
| Total noncurrent assets: | 11 | 8 | 9 | 18 | 78 | 26 | ||
| TOTAL ASSETS: | 85 | 92 | 119 | 148 | 181 | 90 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 1 | 4 | 3 | 4 | 3 | 5 | ||
| Accounts payable | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Accrued liabilities | 3 | |||||||
| Employee-related liabilities | 2 | 2 | 2 | 2 | ||||
| Taxes payable | 2 | |||||||
| Debt | 1 | |||||||
| Deferred revenue and credits | ✕ | ✕ | 6 | 21 | ||||
| Other undisclosed current liabilities | 7 | 6 | 5 | 3 | 52 | |||
| Total current liabilities: | 9 | 9 | 14 | 28 | 55 | 5 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 5 | |||||||
| Finance lease, liability | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Operating lease, liability | 5 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 2 | 4 | 5 | 4 | 17 | |||
| Deferred revenue and credits | ✕ | ✕ | 1 | 4 | 17 | |||
| Other liabilities | 2 | 4 | 4 | |||||
| Total noncurrent liabilities: | 7 | 4 | 5 | 4 | 17 | |||
| Total liabilities: | 17 | 14 | 19 | 33 | 72 | 5 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 68 | 79 | 99 | 115 | 109 | 86 | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Treasury stock, value | (0) | (0) | (0) | |||||
| Additional paid in capital | 215 | 214 | 210 | 205 | 199 | 174 | ||
| Accumulated deficit | (147) | (136) | (111) | (90) | (90) | (89) | ||
| Total stockholders' equity: | 68 | 79 | 99 | 115 | 109 | 86 | ||
| TOTAL LIABILITIES AND EQUITY: | 85 | 92 | 119 | 148 | 181 | 90 | ||
Income statement (P&L) ($ in millions)
| 9/30/2019 TTM | 6/30/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | ||
|---|---|---|---|---|---|---|---|
| Revenue, net | ✕ | ✕ | 0 | 0 | 1 | 2 | |
| Gross profit: | 28 | 42 | 24 | 39 | 47 | 2 | |
| Operating expenses | (45) | (46) | (47) | (38) | (49) | (27) | |
| Operating income (loss): | (17) | (4) | (22) | 2 | (2) | (25) | |
| Nonoperating income | 2 | 2 | 1 | 1 | 1 | 0 | |
| Investment income, nonoperating | 1 | 2 | 1 | 1 | 1 | 0 | |
| Other nonoperating income (expense) | 0 | (0) | (0) | (0) | (0) | ||
| Interest and debt expense | (0) | ||||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 0 | ||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (15) | (2) | (21) | 3 | (1) | (24) | |
| Loss from equity method investments | (0) | (0) | |||||
| Income (loss) from continuing operations before income taxes: | (15) | (2) | (21) | 3 | (1) | (24) | |
| Income tax expense | (0) | (0) | (0) | (2) | |||
| Income (loss) before gain (loss) on sale of properties: | (15) | (2) | (21) | 0 | (1) | (24) | |
| Other undisclosed net loss | (0) | ||||||
| Net income (loss) available to common stockholders, diluted: | (15) | (2) | (21) | 0 | (1) | (24) | |
Comprehensive Income ($ in millions)
| 9/30/2019 TTM | 6/30/2019 | 6/30/2018 | 6/30/2017 | 6/30/2016 | 6/30/2015 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | (15) | (2) | (21) | 0 | (1) | (24) | |
| Comprehensive income (loss), net of tax, attributable to parent: | (15) | (2) | (21) | 0 | (1) | (24) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.